Tellgen Corp (300642) - Total Assets
Based on the latest financial reports, Tellgen Corp (300642) holds total assets worth CN¥2.01 Billion CNY (≈ $294.79 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Tellgen Corp to assess how comfortably operating cash covers total debt obligations.
Tellgen Corp - Total Assets Trend (2012–2025)
This chart illustrates how Tellgen Corp's total assets have evolved over time, based on quarterly financial data. See 300642 net assets for net asset value and shareholders' equity analysis.
Tellgen Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Tellgen Corp's total assets of CN¥2.01 Billion consist of 46.7% current assets and 53.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.8% |
| Accounts Receivable | CN¥204.46 Million | 9.9% |
| Inventory | CN¥98.51 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.81 Million | 4.2% |
| Goodwill | CN¥185.08 Million | 9.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Tellgen Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300642 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tellgen Corp's current assets represent 46.7% of total assets in 2025, a decrease from 76.2% in 2012.
- Cash Position: Cash and equivalents constituted 18.8% of total assets in 2025, down from 49.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 9.9% of total assets.
Tellgen Corp Competitors by Total Assets
Key competitors of Tellgen Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
Tellgen Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.38 | 13.95 | 8.22 |
| Quick Ratio | 4.77 | 12.26 | 6.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥718.00 Million | CN¥814.47 Million | CN¥832.61 Million |
Tellgen Corp - Advanced Valuation Insights
This section examines the relationship between Tellgen Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 17.6% |
| Total Assets | CN¥2.06 Billion |
| Market Capitalization | $300.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tellgen Corp's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tellgen Corp's assets grew by 17.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tellgen Corp (2012–2025)
The table below shows the annual total assets of Tellgen Corp from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.06 Billion ≈ $300.98 Million |
+17.60% |
| 2024-12-31 | CN¥1.75 Billion ≈ $255.93 Million |
+4.12% |
| 2023-12-31 | CN¥1.68 Billion ≈ $245.80 Million |
+0.90% |
| 2022-12-31 | CN¥1.66 Billion ≈ $243.60 Million |
+11.07% |
| 2021-12-31 | CN¥1.50 Billion ≈ $219.33 Million |
+9.26% |
| 2020-12-31 | CN¥1.37 Billion ≈ $200.73 Million |
+10.05% |
| 2019-12-31 | CN¥1.25 Billion ≈ $182.40 Million |
+13.03% |
| 2018-12-31 | CN¥1.10 Billion ≈ $161.38 Million |
+17.93% |
| 2017-12-31 | CN¥935.16 Million ≈ $136.84 Million |
+174.62% |
| 2016-12-31 | CN¥340.53 Million ≈ $49.83 Million |
+47.54% |
| 2015-12-31 | CN¥230.80 Million ≈ $33.77 Million |
+42.67% |
| 2014-12-31 | CN¥161.77 Million ≈ $23.67 Million |
+26.46% |
| 2013-12-31 | CN¥127.92 Million ≈ $18.72 Million |
+57.27% |
| 2012-12-31 | CN¥81.34 Million ≈ $11.90 Million |
-- |
About Tellgen Corp
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more